FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid symptom relief.

BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration...

TUESDAY, Feb. 4, 2025 -- The U.S. Food and Drug Administration (FDA) has approved the first-ever clinical trials testing pig kidney transplants in...

South San Francisco, CA -- February 4, 2025 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food...

PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic to...

MONDAY, Feb. 3, 2025 -- The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with...

Food and Drug Administration (FDA) approved a new medication called Journavx (suzetrigine) to treat moderate to severe acute pain in adults. This...

On January 16, 2025, the Food and Drug Administration approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic...

On January 16, 2025, the Food and Drug Administration granted traditional approval to acalabrutinib with bendamustine and rituximab for adults with...

For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a...